Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04624555 · ClinicalTrials.gov registry record
The Utility and Feasibility of Mt-sDNA as a Surveillance Procedure in Colorectal Cancer Survivors
A clinical trial of Adenocarcinoma of the Rectum and Adenocarcinoma of the Colon, sponsored by Case Comprehensive Cancer Center.
- Recruiting
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT04624555: Recruiting study of Adenocarcinoma of the Rectum and Adenocarcinoma of the Colon, sponsored by Case Comprehensive Cancer Center.
NCT04624555 is a study of Adenocarcinoma of the Rectum and Adenocarcinoma of the Colon that is actively recruiting participants, run by Case Comprehensive Cancer Center. The registered enrollment target is 50 participants, below the 907-participant average among 11 other Adenocarcinoma of the Rectum trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04624555, a study of Adenocarcinoma of the Rectum and Adenocarcinoma of the Colon, is actively recruiting participants, sponsored by Case Comprehensive Cancer Center.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to determine whether testing of stool for a panel of markers will enable us to detect polyps and cancer compared to standard testing.
Primary Outcome
Compare the results between mt-sDNA (categorized as a single positive or negative result) with the findings at colonoscopy, the "gold standard". Colonoscopy will be considered positive if an adenoma or carcinoma is found and otherwise negative. Sensitivity is defined as True Positive (TP)/(TP+ False Negative (FN))
Conditions Studied
Study Locations (1)
Ohio
- University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-10-31 |
| Est. Completion | 2026-01-30 |
What NCT04624555 shows while recruiting
NCT04624555 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 907-participant average among 11 other Adenocarcinoma of the Rectum trials with a reported enrollment target (94% lower).
The record links to 5 conditions, with Adenocarcinoma of the Rectum appearing as the primary indexed condition, and to 0 interventions.
NCT04624555 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT04624555 about?
NCT04624555 is a clinical study titled "The Utility and Feasibility of Mt-sDNA as a Surveillance Procedure in Colorectal Cancer Survivors". The purpose of this research study is to determine whether testing of stool for a panel of markers will enable us to detect polyps and cancer compared to standard testing.
What is the current status of trial NCT04624555?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2022-10-31. Estimated completion is 2026-01-30.
What conditions does trial NCT04624555 study?
This clinical trial studies the following conditions: Adenocarcinoma of the Rectum, Adenocarcinoma of the Colon, Stage III Colorectal Cancer, Stage I Colorectal Cancer, Stage II Colorectal Cancer.
Who is sponsoring clinical trial NCT04624555?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04624555 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenocarcinoma of the Rectum
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04624555's enrollment target sits among peer trials
50 4th of 11 higher than 8 of 11 other Adenocarcinoma of the Rectum trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Adenocarcinoma of the Rectum trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
RECRUITING
-
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
RECRUITING · NA
-
A Study of Response to Standard Treatment Before Surgery in People With Rectal Cancer
RECRUITING · NA
-
A Study of Tucatinib and Trastuzumab in People With Rectal Cancer
RECRUITING · Phase 2
-
Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum
COMPLETED · Phase 2
-
Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI